<DOC>
	<DOCNO>NCT01174108</DOCNO>
	<brief_summary>Background : - Stem cell transplant related donor ( allogenic stem cell transplant ) use treat individual certain kind severe blood disease cancer , severe anemia . Allogenic stem cell transplant encourage growth new bone marrow replace recipient . Because stem cell transplant serious complication , researcher interest develop new approach stem cell transplant reduce likelihood complication . - By reduce number white blood cell include blood take stem cell collection process , replace small amount white blood cell collect prior stem cell donation , stem cell transplant may less likely cause severe complication recipient . Researchers investigate whether alter stem cell transplant donation procedure manner improve likelihood successful stem cell transplant few complication . Objectives : - To evaluate new method stem cell transplantation may reduce possibly severe side effect transplant rejection recipient . Eligibility : - Recipient : Individuals 4 80 year age diagnose blood disease treat allogenic stem cell transplant , relate donor provide stem cell . - Donor : Individuals 4 80 year age relate recipient eligible donate blood . Design : - All participant screen physical examination medical history . - DONORS : - Donors undergo initial apheresis procedure donate white blood cell . - After initial donation , donor receive injection filgrastim release bone marrow cell blood . - After 5 day filgrastim injection , donor apheresis donate stem cell present blood . - RECIPIENTS : - Recipients provide initial donation white blood cell use research purpose . - From 7 day stem cell transplant , participant admit inpatient unit National Institutes Health Clinical Center receive regular dos cyclophosphamide , fludarabine , anti-thymocyte globulin suppress immune system prepare transplant . - After initial chemotherapy , participant receive donate white blood cell stem cell single infusion . - After stem cell white blood cell transplant , participant regular dos cyclosporine methotrexate prevent rejection donor cell . Participants three dos methotrexate within week transplant , continue take cyclosporine 4 month transplant . - Participants remain inpatient care 1 month transplant , follow regular visit 3 year periodic visit thereafter evaluate success transplant side effect .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation Severe Aplastic Anemia Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With Reduced Dose Non-Mobilized Donor T-cells</brief_title>
	<detailed_description>Allogeneic hematopoietic stem cell transplantation ( aHSCT ) cure patient variety bone marrow failure syndrome ( BMFS ) include severe aplastic anemia ( SAA ) , paroxysmal nocturnal hemoglobinuria ( PNH ) myelodysplastic syndrome ( MDS ) associate cytopenia . Patients BMFS traditionally transplant bone marrow ( BM ) stem cell source . Although chronic graft versus host disease ( cGVHD ) occur less commonly BM compare filgrastim ( G-CSF ) mobilize peripheral blood stem cell ( PBSC ) transplant , BM allografts low CD34+ progenitor cell number , increase risk graft rejection heavily transfuse BMFS patient 15-20 percent . To overcome risk , group develop novel transplant approach patient high risk graft rejection utilized cyclophosphamide , fludarabine anti-thymocyte globulin ( ATG ) conditioning follow infusion CD34+ cell rich , T-cell replete G-CSF mobilize PBSC allograft . Remarkably , 56 consecutive BMFS patient multiple risk factor graft rejection underwent transplant approach graft rejection occur , patient achieve complete donor lymphohematopoietic chimerism . Unfortunately , recipient G-CSF mobilize PBSC high incidence chronic GVHD historically observe BM transplantation ( 72 percent vs. 50 percent cumulative incidence cGVHD 1 year respectively ) . G-CSF mobilize PBSC transplant contain approximately 20 fold high dose T-cells undergone TH- 2 type cytokine polarization , factor likely contribute high incidence cGVHD . In protocol , attempt prevent graft failure reduce incidence cGVHD transplant high number CD34+ select PBSC co-infused reduce dose non-mobilized donor T-cells undergone TH-2 cytokine polarization . Subjects BMFS high risk graft rejection undergo allogeneic stem cell transplantation HLA identical sibling match unrelated donor use identical condition regimen utilized protocol 99-H-0050 . Using Miltenyi CliniMACs system , recipient receive allograft day 0 contain donor CD34+ cell positively select T-cell deplete follow G-CSF mobilization ( goal CD34+ cell dose 5 time 10 ( 6 ) CD34+ cell /kg recipient ) combine 2 time 10 ( 7 ) cells/kg non-mobilized CD3+ T-cells previously collect cryopreserved donor apheresis prior G-CSF mobilization . Primary objective : To evaluate whether administer CD34+ select , T-cell deplete peripheral blood stem cell graft concomitant infusion non-mobilized donor T-cells dose match T-cell dose infuse historical bone marrow transplant cohort reduce incidence cGVHD 1 year observe conventional bone marrow transplant ( 50 percent ) without increase risk graft failure . This trial design allow trial stop early unlikely reduce proportion one year cGVHD 50 percent combine event rate fail donor engraftment treatment relate mortality ( TRM ) day 100 exceeds 20 percent . The primary endpoint study cGVHD day 365 . Secondary end point include transplant related mortality , engraftment , degree donor-host chimerism , incidence acute chronic graft versus host disease ( GVHD ) , transplant relate morbidity overall survival . Health related quality life also assess secondary outcome measure pre-transplant , 30 100 day post transplant every 6 month 5 year post transplant .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<criteria>INCLUSION CRITERIA : Recipient : Patients diagnose one follow hematologic disease associate reasonable longevity , show curable allogeneic BMT concern high procedural mortality conventional BMT may delay prevent treatment : 1 ) Paroxysmal nocturnal hemoglobinuria ( PNH ) associate lifethreatening thrombosis , and/or cytopenia , and/or transfusion dependence and/or recurrent debilitate hemolytic crisis 2 ) Severe aplastic anemia ( SAA ) pure red cell aplasia ( PRCA [ acquire congenital ] ) associate transfusion dependence and/or neutropenia patient candidate , fail immunosuppressive therapy 3 ) Refractory anemia ( RA ) RARS MDS patient associated transfusion dependence and/or neutropenia . Ages 4 80 ( inclusive ) , weight &gt; 18kg Availability HLA identical single HLA locus mismatch family donor 10/10 match unrelated donor allelic level ( HLA alleles A , B , C , DR , DQ ) . Telomere Length Testing In patient suspicion familial bone marrow failure syndrome ( BMFS ) exist , TERC TERT mutation test perform protocol 04H0012 perform elsewhere prior enrol 04H0012 . EXCLUSION CRITERIA : Recipient : following Major anticipate illness organ failure incompatible survival PBSC transplant Diffusion capacity carbon monoxide ( DLCO ) &lt; 40 % predict ( patient age 10 may exclude criterion difficulty perform test correctly thus unable DLCO assess ) use DL Adj DL/VA/Adj . Left ventricular ejection fraction &lt; 40 % ( evaluated ECHO ) &lt; 30 % ( evaluated MUGA ) Serum creatinine great 2.5mg/dl creatinine clearance le 50 ml/min 24 hr urine collection Serum bilirubin great 4 mg/dl , transaminases great 5 time upper limit normal Pregnant lactate Fanconi anemia ECOG performance status 3 ( See Bone &amp; Marrow Transplant Consortium Supportive Care Guidelines HSCT Recipients ) Other malignant disease liable relapse progress within 5 year , exception separate hematologic malignancy allogeneic stem cell transplant show potentially curative . Inability comprehend investigational nature study provide inform consent . The procedure explain subject age 8 17 year formal consent obtain parent legal guardian . INCLUSION CRITERIA : Related Donor : HLA identical single HLA mismatch family donor Age great equal 4 less equal 80 year old Weight &gt; 18 kg If suspicion familial BMFS recipient , donor must underong genetic test gene associate BMFS perform CLIAcertified laboratory , prior enrol protocol . EXCLUSION CRITERIA : Related Donor : follow Pregnant lactate Unfit receive filgrastim ( GCSF ) undergo apheresis ( history stroke , MI , unstable angina , uncontrolled hypertension , severe heart disease palpable spleen ) HIV positive ( donor positive HBV , HCV HTLVI/II , T.cruzi [ Chagas ] may use discretion investigator follow counsel approval recipient ) Sickling hemoglobinopathy include HbSS HbSC . Donors HbAS acceptable Inability donor guardian donor comprehend investigational nature study provide inform consent . INCLUSION CRITERIA &amp; EXCLUSION CRITERIA : Unrelated Donor The NMDP unrelated donor inclusion criterion use outline document ( link ) . Donor eligibility complete per NMDP standard accordance recent stringent FDA guideline .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 3, 2017</verification_date>
	<keyword>Myelodysplastic Syndrome ( MDS )</keyword>
	<keyword>Severe Aplastic Anemia</keyword>
	<keyword>Pure Red Cell Aplasia</keyword>
	<keyword>Paroxysmal Nocturnal Hemoglobinuria ( PNH )</keyword>
	<keyword>Miltenyi CD34 Reagent System</keyword>
	<keyword>Allogeneic Stem Cell Transplant</keyword>
</DOC>